OB-756 is under clinical development by Hangzhou East China Pharmaceutical Group and currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OB-756’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OB-756 overview

OB-756 is under development for the treatment of rheumatoid arthritis, primary myelofibrosis, post-essential thrombocythemia myelofibrosis (Post-ET MF) and post-polycythemia vera myelofibrosis (PPV-MF). The drug candidate is administered by the oral route. The drug candidate is an OB-756 film. The drug candidate acts by targeting Janus kinase 1 (JAK-1) and Janus kinase 2 (JAK-2).

For a complete picture of OB-756’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.